# Supporting Information

## Supporting Information — Human malignancies show increased occupancy of a shared region of normal-cell regulatory space

**Theodor Spiro** · Vaika Inc. · Archived at Zenodo: https://doi.org/10.5281/zenodo.20542130

This SI contains extended methods (Notes S1–S5), the control notes S-A to S-M, two notes that are primary evidence about the method — **Note S-N** (the panel evaluated without cancer data) and **Note S-O** (independent reconstructions of the catalog, which is where the catalog-dependence of the anchor is established), plus **Note S-Q** (the complexity control run across the whole convergence region and the gene-symbol recovery audit), **Note S-R** (the pre-registration and per-contrast detail of the five *in vitro* transformation series of Fig. 6), **Note S-T** (the pre-registered activity-scoring test, which is where the measurement-level dependence of the anchor is established), and **Note S-U** (what the twelve CELLxGENE Census cohorts of the panel actually resolve to, with Table S-Q). Notes S-E and S-S were withdrawn and their letters are left unused, and Tables S-P and S-Q carry letters for the same reason. There are fifteen supplementary figures (S1–S15), each composed of one to three parts labelled I, II and III, and twelve supplementary tables (S1–S9, S9b, S-P and S-Q), plus Table 1 in the main text. Tables S1, S2, S3, S4, S6 and S7 are provided as attached CSV files (`tableS1_datasets.csv`, `tableS2_ranking154.csv`, `tableS3_invariance.csv`, `tableS4_modules.csv`, `tableS6_complexity.csv`, `tableS7_core_signature.csv`); all others are inline.

---

## Note S1 — Full methods

**Modules.** A regulatory module is defined by four operational criteria: a sensor input; a transcription-factor output with documented targets; a negative-feedback target enabling cyclical operation; and receptor-field specificity. Screening ~75 candidate signaling and metabolic axes (KEGG, Reactome, primary literature) against these criteria yielded 44 modules. Module activity is scored as the mean log-normalized expression of component genes.

**Eigenspace.** The 154 × 44 Human Protein Atlas single-cell matrix (Uhlén et al., 2015; scRNA-seq data, not protein measurements) was z-scored per module and decomposed by PCA. Nine components were retained by the Kaiser criterion (73.8% of variance). Bootstrap resampling with replacement (n = 154, 500 iterations) gives eigenvector stability that falls monotonically with the axis: 0.75–0.99 for PC1–PC6 and 0.53–0.71 for PC7–PC9 (Fig. S1-I). The 100-iteration field stored with the reference object (0.63–0.99 and 0.40–0.54, with PC8 below PC9) does not reproduce under this recipe and is withdrawn; no code for it survives.

**Two HPA calibrations.** The eigenspace is built on the *pseudobulk* HPA reference. For per-cell tumor projection, the reference is re-derived under the *single_cell_scaled* calibration — the same `normalize_total(1e4)+log1p` preprocessing applied to the tumor data — so per-cell z-scores are commensurate; projecting under the pseudobulk calibration collapses tumor cells to low-complexity targets (scale mismatch). All cancer projections use single_cell_scaled.

**Cancer projection.** Per cancer: load malignant cells; remap ENSEMBL→symbol where needed; uppercase and de-duplicate gene names; quality-filter to n_genes ≥ 1000; `normalize_total(1e4)+log1p` if max > 100; score 44 modules (`mean_raw`); z-score against the single_cell_scaled reference; project through the 44×9 loading matrix; record the top-1 nearest of 154 cell-type centroids (cosine).

**Convergence projection (Fig. S4-I).** Malignant cells of two contrasting cancers (B-ALL, neuroblastoma; ≤2,000 cells each, n_genes ≥ 1000) are projected onto two interpretable 9-D directions — cosine to the core centroid (convergence axis) and cosine to a neural-program centroid (brain excitatory/inhibitory neurons and adrenal medulla cells — the neuronal/sympathoadrenal program neuroblastoma derives from; neural-program axis) — with 20/50/80% KDE density contours over the 154 normal cell types. B-ALL median core-cosine 0.86 (neural-program 0.07); neuroblastoma 0.59 (neural-program 0.47). Positions are static snapshots, not trajectories. These axes are used because the raw PC1–PC2 projection does not resolve the convergence (below).

**Convergence map (Fig. S4-II).** The 154 normal cell types are colored by the mean across 25 cancers of the fraction of malignant cells assigned to each (top-1), painted on the PC1–PC2 layout. Color carries the convergence statistic; position is eigenspace location, shown for context only. A raw projection of per-cell tumor coordinates into PC1–PC2 and re-derivation of nearest-neighbor assignment recovers only 8.2% core-assignment for B-ALL against 60.8% in the full 9-D space, and 6.8% against 23.9% pooled over all 25 cancers; any two cancers' raw clouds overlap across the whole manifold — convergence is a high-dimensional nearest-neighbor property, not a 2-D location. (Both arms of each pair are recomputed on the current 83,819-cell panel under the single quarantine convention; `scripts/E42_2d_vs_9d.py`.)

**Target identification (non-circular).** Cell types are ranked by cross-cancer *recurrence* (number of the 25 cancers in which the cell is among the five most frequent top-1 assignments), not by proximity to a pre-chosen centroid. The two-cell core (megakaryocyte, cytotrophoblast) leads this ranking with a clear margin (cytotrophoblast 18/25, megakaryocyte 18/25) and is independently the only pair leading the *median per-cancer fraction* (depth) ranking. No third cell leads on both metrics (Table S2; Fig. S6-I). The erythrocyte and platelet — post-cellular bodies — are excluded (Note S3); the erythrocyte is also the documented low-complexity artifact (Fig. S5-I/S4).

**Enrichment.** Reported as fold-enrichment over the k/152 chance baseline (152 candidates after the erythrocyte/platelet quarantine; Note S-K) across three principled boundaries (top-2 core, 18.2×; top-4 neighbourhood, 15.9×; top-14 broader region, 8.4×) to show boundary-independence: boundaries are defined by rank in the cross-cancer recurrence ranking, and all three are computed on the same 83,819-cell panel: the top-2 core captures 23.9% of malignant cells (chance 2/152 = 1.32%, 18.2×), the top-4 neighbourhood 41.9% (chance 2.63%, 15.9×) and the top-14 broader region 76.9% (chance 9.21%, 8.4×). Region coherence is the mean pairwise eigenspace cosine among the convergent cells (0.77 vs −0.01 for random pairs).

**Progression.** Within-cancer, patient-level aggregation with n_genes control; HCC clinical stage (Lu 2022) and colorectal grade/T-stage/nodal status (Pelka 2021); Table S5.

**Convergence contraction (Fig. 2).** Each cancer's malignant 9-D centroid (mean over QC-passing malignant cells) is paired with its normal cell of origin in the 154 reference (e.g. HCC→hepatocyte, B-ALL→B-cell, osteosarcoma→fibroblast, seminoma→spermatogonia; full map in Table S8). The contraction is the ratio of the mean pairwise cosine distance among the 25 origins to that among the 25 malignant centroids. Significance is **not** taken against 2,000 random draws of 25 normal cell types (a Stayton-type convergence test): that null is **superseded**, because it ignores the averaging itself, and the fold-contraction it produced is withdrawn. The test that stands is the matched-averaging null of coherent normal micro-populations, which is what the main text and Fig. 2 report — see **Note S-G**, which is the Methods statement for this figure. A replicator should read Note S-G before reproducing this panel. The MDS basin (Fig. S4-II) is a metric-MDS embedding of the origins + malignant centroids on their full 9-D distance matrix (all axes, not leading PCs).

**Panel expansion to 25.** Six datasets were added to span origin classes absent from the original nineteen: small-cell lung (neuroendocrine) and gastric (Census, malignant = epithelial compartment); osteosarcoma (GSE162454) and Ewing sarcoma (GSE130024, PDX) for mesenchymal origin; embryonal germ-cell tumor (GSE228501) and seminoma (GSE197778) for germ-cell origin. For GEO datasets without author malignant annotations, malignant cells were identified by Leiden clustering and lineage markers (osteoblastic SATB2/RUNX2/COL1A1; Ewing CD99/NKX2-2; germ-cell POU5F1/SALL4/KIT) versus immune (PTPRC). Per-dataset detail in Table S1.

**Geometry / coordinate invariance.** Convergent-region compactness was tested in three coordinate systems — PCA (9-D), varimax-rotated (6-D), and diffusion-map (8-D) — against a null of random equal-size cell subsets (Note S4, Table S3).

**Disease negative control and within-patient matched test (Fig. 4; Figs. S11-II, S12).** The identical pipeline (QC n_genes ≥ 1000 → normalize_total(1e4)+log1p → 44-module mean_raw scoring → z vs single_cell_scaled HPA → 9-PC projection → top-1 nearest of 154) was first validated to reproduce the cancer core fractions (Gastric 16.5% vs panel 16.1%; AML 20.4% vs 21.3%), then applied to four chronic-disease atlases with matched-normal arms: rheumatoid arthritis (excluded — median 286 genes/cell, below the QC floor), idiopathic pulmonary fibrosis (Habermann 2020), diabetic kidney disease, and Alzheimer's (Grubman 2019). Core fraction was computed per arm with the erythrocyte low-complexity default reported separately; tissue baselines: kidney 0.5–1.0%, neural 7.6%, lung epithelium 16.1% (Control) / 19.9% (IPF) on the raw core and 7.6% / 8.9% shape-only (22 donors; Fig. S12), breast epithelium 25% (Wu 2021). For the within-patient test, malignant vs patient-matched normal epithelium of the *same* tissue was compared per patient (≥ 20 cells/arm) by paired Wilcoxon plus a sign test, across every tissue with paired tumour-and-adjacent-normal single-cell data. Low-baseline tissues: Pelka colorectal (46 patients, malignant median 18.9% vs normal 4.7%, 43/46, *P* = 9 × 10⁻¹³; separate normal samples, clean); an independent colorectal cohort (Human Tumor Atlas via Census, 23/25, one-sided *P* = 2 × 10⁻⁶); kidney (clear-cell RCC, Census, 6/7, median 11.5% vs 5.3%, *P* = 0.055); and liver (Lu HCC — 8 of its 10 patients have ≥ 20 hepatocytes in *both* the tumour and adjacent-normal arms, distinct from the 10-patient stage-trend analysis in the main text which only requires tumour-side stage metadata — 5/8, 19.4% vs 10.9%, *P* = 0.074). Pooled across these 86 patients, 77 are deeper (sign-test *P* = 7 × 10⁻¹⁵); a mixed-effects model with a dataset random intercept, which credits the between-dataset clustering, gives +13.0 points (SE 1.87, *z* = 6.95, one-sided *P* = 2 × 10⁻¹²). **Retracted negative control.** An earlier version of this work reported lung adenocarcinoma (Census, 2/8, median 14% for the “tumour” arm against 27% for the patient-matched adjacent-normal arm of the same cohort) as a high-baseline tissue showing no deepening. Three different normal lung values appear in this paper and they are three different things: 26.7% is that cohort's *patient-matched adjacent normal*, 11.7% is a *pool of healthy Census donors* (Fig. S11-IIB), and 23.4% is the *matched normal arm of the GSE131907 cohort* (Fig. S11-IIA). That reading is withdrawn: the Census "tumour" arm assembled by the broad epithelial filter is only ~9% annotated-malignant cells and ~91% normal-adjacent alveolar epithelium, so it was diluted to the normal baseline. With cleanly identified malignant cells (GSE131907) lung deepens like every other tissue tested — 23.4% → 39.0% raw in 10 of 10 patients (*P* = 0.002) and 18.2% → 30.3% shape-only in 9 of 10 (*P* = 0.004) (Fig. S11-II, Note S-J). No baseline-gating claim is made anywhere in this paper. Wu BRCA is uninformative (its "normal epithelial" cells are intratumoral, not separate adjacent-normal), and pooled cross-dataset ratios are vulnerable to Simpson's paradox (Lu pooled 4.6× collapses per patient); only the within-patient paired test is reported as causal. **Prostate — an unresolved tissue, reported as such.** In a 15-patient paired tumour/adjacent-benign atlas (CELLxGENE) prostate shows no within-patient deepening (7 of 15 patients). We previously set it aside as a saturated high-baseline tissue (~15%); that justification rested on the baseline-gating hypothesis we now retract, so we do not use it. Re-analysing an independent paired prostate cohort (Song 2022, GSE176031, four patients with paired benign and tumour epithelium) does not resolve it either: there the benign prostate baseline is *low* (2.1%, near the chance level) and the tumour arm reaches only 3.8% (paired *P* = 0.38, n.s.). The two prostate datasets therefore disagree about the baseline itself, and neither shows deepening. Prostate is counted as a tested tissue with a negative result, and the claim in the main text is stated accordingly as deepening in every tissue tested *except prostate*, whose cohorts are mutually inconsistent.

---

## Note S2 — NPAS4 leave-one-out

The single neuron-restricted module (NPAS4) does not shape the cross-tissue eigenspace. Rebuilding on 43 modules (pseudobulk basis, matching the canonical reference) reproduces all nine components with per-PC eigenvector cosine ≥ 0.95 (mean 0.99 over PC1–PC6), so all cross-tissue statistics transfer unchanged to the 44-module catalog. NPAS4 is retained for compatibility with neural single-cell datasets; its module score is near zero in non-neural cell types and does not affect cross-tissue analyses.

---

## Note S3 — Low-complexity artifact and quality control

Per-cell module scores depend on transcriptome complexity: cells with few detected genes carry degenerate profiles that map preferentially to low-complexity normal targets (erythrocytes median 890 genes, late spermatids 763 — both *below* the QC floor; Table S6). Screening 22 candidate cancer datasets by median genes/cell, five fall below 1,000 (AML 137, OralSCC 639, MM 665, Follicular 831, Gastric 912; Fig. S5-IA). These are excluded; AML and MM are replaced by GEO cohorts that pass the floor (van Galen 2019, Seq-Well, median ~1,050; Ledergor 2018, InDrops), the other three dropped. The final panel is 25 — nineteen passing the initial screen plus six added (two mesenchymal sarcomas, two germ-cell tumors, one neuroendocrine, one new epithelial tissue) to span all major origin classes (Note S1). The gastric dataset excluded here (median 912) is the original screen cohort; it is **not** the gastric in the final panel — that is a different CELLxGENE Census stomach dataset (the "one new epithelial tissue" added), whose twenty-three tumour donors are however the same twenty-three patients as the paired gastric test of §5, which is why that test is no longer described as held out (Note S-U), with median 1,169 genes/cell, above the floor (54% of its cells pass the per-cell n_genes ≥ 1000 filter). After QC, convergence-fraction shows no association with dataset cell count (Spearman ρ = +0.14, P = 0.60).

The erythrocyte family is excluded from the recurrence ranking and the main-panel figures specifically: before exclusion it ranks third (16 of 25), filling the gap between the core and the rest (Table S2 carries each cell's pre-quarantine occupancy; Note S-K). The core is not a residual artifact — megakaryocyte- and cytotrophoblast-assigned cells carry median 1,396 and 2,430 detected genes, well above the floor (Fig. S5-IB).

**Platform / label-quality.** Convergence-fraction ordering is sensitive to malignant-label quality (three cancers carry heuristic or Census labels; a colon dataset's author-validated relabeling moved it from 13% to 36%) and, despite uniform QC, to residual platform effects (one InDrops dataset; the rest 10x / Census / Seq-Well). Per-dataset provenance in Table S1.

**Marker-annotated additions do not drive the result.** Four of the six added cancers carry marker-based rather than author malignant labels (both sarcomas, both germ-cell tumors). Dropping all four and recomputing on the remaining 21 leaves the central numbers essentially unchanged: the malignant compartment's mean pairwise cosine distance is 0.166 across the full 25 and 0.174 across the 21 (the drop-4 value; not to be confused with the 0.174 obtained when only 25 cells per cancer are averaged, Fig. 2B) (both far below the 0.99 separating the tissues of origin), and the core holds rank 2 and 3 of 154 in the full-9-D cosine to the malignant attractor in both panels. The marker-based cancers neither create the convergence nor inflate the core's standing.

---

## Note S4 — Coordinate invariance attaches to the region, not the bare core

The convergent **region** (the four-cell majority-enriched neighborhood) is an unusually tight subset of the 154 cell types, and that tightness is coordinate-invariant: it is significant in both the linear PCA basis (percentile 0.005) and the varimax rotation (0.001), and directional in the diffusion-map embedding (0.072), confirming the convergence is geometry, not an artifact of the linear PCA basis (Table S3). The two-cell **core** alone is too small for the compactness statistic (a single pairwise distance; percentile 0.07–0.24, not significant) — identity attaches to the core (which two cells), invariance to the region (whether the neighborhood is tight). The two carriers are kept distinct.

**Table S3. Coordinate-invariance compactness, region versus bare core, in three bases** (`tableS3_invariance.csv`).

| Set | Coordinates | Percentile | z |
|---|---|---:|---:|
| neighborhood (4) | PCA (9-D) | **0.005** | −2.09 |
| neighborhood (4) | varimax (6-D) | **0.001** | −2.38 |
| neighborhood (4) | diffusion (8-D) | 0.072 | −0.83 |
| core (2) | PCA (9-D) | 0.113 (ns) | −1.13 |
| core (2) | varimax (6-D) | 0.073 (ns) | −1.32 |
| core (2) | diffusion (8-D) | 0.243 (ns) | −0.53 |

The diffusion embedding is no tighter than PCA, consistent with the manifold being only weakly curved (PCA adequate). Compactness in the pseudobulk calibration is diffuse (percentile ~0.46); the tightness is specific to the single_cell_scaled calibration used for tumor projection, as expected from the calibration's construction. This is not calibration-shopping: Note S-H shows the pseudobulk alternative degenerates independently, on normal single cells with no cancer involved, collapsing 99.6% of them onto erythroid targets — so the diffuseness here is a property of the wrong calibration for single-cell data, not evidence that the tightness was selected for.

---

## Note S5 — Metabolic-enzyme stratification (secondary)

On the normal side, convergent-region cells are glycolytic-oxidative-active and distinct from NAMPT-pathway inflammatory cells; on the cancer side the corresponding stratification is null. Reported as a secondary observation only; it does not bear on the convergence result.

---

## Supplementary figures

Sixteen numbered figures. Several are composites: their blocks carry Roman part labels (I, II, III),
and a block's own sub-panels keep their letters, so a part is cited as Fig. S5-I and a sub-panel of
it as Fig. S5-IB. Grouping and composition: `scripts/build_SI_consolidate.py`; the ordered list with
captions: `scripts/si_figures_v12.py`.

- **Fig. S1.** The nine axes: bootstrap stability per axis, and how much of each axis biological family explains.
- **Fig. S2** (`v7_fig_E2_redundancy.png`). Module redundancy: 6 of 946 pairs exceed |r| > 0.7, mean |r| = 0.21.
- **Fig. S3** (`v7_fig_axes.png`). Each principal axis against an external, module-free quality signature.
- **Fig. S4.** Where the cancers land, three ways: a converging against a non-converging cancer, the normal-cell map, and the per-cell-type convergence heatmap.
- **Fig. S5.** The transcriptome-complexity trap (QC screen and per-target complexity) and the megakaryocyte complexity control.
- **Fig. S6.** Ranking the candidate targets two ways: breadth × depth with every candidate labelled, and the cross-cancer recurrence ranking.
- **Fig. S7.** How much depends on the module catalog: the two matched nulls, the module-drop rebuild, and the gene-level reproduction.
- **Fig. S8** (`v7_fig_duetprofile.png`). The core against the normal-cell distribution, module by module.
- **Fig. S9** (`v7_figS28_reprogramming.png`). The named target in an independent system with no cancer in it (suggestive only).
- **Fig. S10** (`v7_figS19_speccurve.png`). Specification curve over 36 analytic crossings.
- **Fig. S11.** The within-patient increase: the paired gastric cohort, corrected high-baseline lung, and the magnitude-removed shape-only check.
- **Fig. S12** (`v7_figS24_fibrosis.png`). The benign-remodelling negative control (idiopathic pulmonary fibrosis).
- **Fig. S13.** Before invasion and after dissemination: colorectal adenoma, breast DCIS and Barrett esophagus, and primary against lymph-node metastasis.
- **Fig. S14** (`v7_figS26_dynamics.png`). The coordinate under targeted therapy, with its complexity control.
- **Fig. S15** (`v7_fig_detuning.png`). What malignancy adds within the shared state (within-patient, colorectal).

## Supplementary tables

- **Table S1** (`tableS1_datasets.csv`). 25 datasets: source, tissue, platform, n cells, label source.
- **Table S2** (`tableS2_ranking154.csv`). Full 154-cell ranking by recurrence and median/mean depth.
- **Table S3** (inline, above; `tableS3_invariance.csv`). Coordinate-invariance compactness, region vs core, three bases.
- **Table S4** (`tableS4_modules.csv`). Per-module contributions to the two-component convergent signature, recomputed across all 25 cohorts. Definition: each cancer's centroid is standardized against the reference (mean and SD over the 154 normal cell types) and unit-normalized; the two-component signature is the unit-normalized mean of the standardized cytotrophoblast and megakaryocyte profiles; the contribution of a module is the elementwise term of the cosine between them, so the 44 contributions sum to that cosine — here 0.711, the mean over the 25 cancers of the cosine between a cancer centroid and the two-component signature in standardized module space. It is not the quantity plotted in Fig. 3A, which is the cosine of each normal cell type to the mean malignant direction in the projected nine-dimensional space (0.89–0.92 for the core). `mean_contribution` and `sd` are taken over the 25 cancers and `pct_positive` is the fraction of cancers in which the term is positive (an earlier version of this table was computed on a 16-cohort panel, which is why its values fell on a k/16 grid; `scripts/E33_fix_tables.py`).
- **Table S5** (inline, below; progression). HCC stage and colorectal grade/T/N.
- **Table S6** (`tableS6_complexity.csv`). Transcriptome-complexity diagnostic: median detected genes for cells assigned to each normal cell type — 144 rows, the reference types that receive at least one assignment out of the 154.
- **Table S7** (`tableS7_core_signature.csv`). The core's target-defining module signature: per-module target-distinctiveness (SD of the core below the other 152 normal cell types), megakaryocyte and cytotrophoblast z-scores, and each module's mean cancer→core contribution (Fig. 4B).
- **Table S8** (`tableS8_origins.csv`). Cancer → normal cell-of-origin mapping and origin class (25 cancers). A *nominal/approximate* annotation: the contraction (Fig. 2) is tested against random 25-cell draws and does not depend on the specific pairings (the origins are near-orthogonal regardless of choice).
- **Table S9** (`tableS9_module_genes.csv`). The 44 regulatory modules and their component (core) genes (206 unique genes); the explicit catalog underlying the eigenspace.

**Table S5. Within-cancer progression (no strong gradient).**

| Cohort | Test | Statistic | n | Verdict |
|---|---|---|---:|---|
| HCC (Lu 2022) | convergence vs clinical stage I–IV | Spearman ρ = +0.40, P = 0.26 | 10 patients | weak positive, not significant; component not excluded |
| Colorectal (Pelka 2021) | convergence vs grade | Mann–Whitney, P > 0.05 | 62 patients | null |
| Colorectal (Pelka 2021) | convergence vs T-stage | Mann–Whitney, P > 0.05 | 62 patients | null |
| Colorectal (Pelka 2021) | convergence vs nodal status | Mann–Whitney, P > 0.05 | 62 patients | null |

n_genes-controlled; convergence is substantial already at the earliest stages sampled.


**Terminology and boundaries (glossary).** *Regulatory module* and *perceptual module* denote the same object; the main text uses "regulatory module" throughout. Region boundaries, used consistently: the **two-cell core** = cytotrophoblast + megakaryocyte; the **three-cell core** = those two plus the migrating cytotrophoblast (used in the control notes; see Note S-K); the **four-cell majority-enriched neighbourhood** and the **14-cell broader region** are successively wider boundaries used only in the boundary-independence check (Table S2), which shows the enrichment survives the choice. *The vocabulary, fixed.* The paper uses several near-synonyms and they are not interchangeable, so each is pinned here. **The region** (equivalently *convergent region*, *convergent state*) is whichever of the four boundaries above is under discussion, and is always qualified in context; it is the object of the claim this paper defends. **The core** without a number means the two-cell core. **The target** is the cell a ranking puts nearest the region — a property of the ranking, not an identification of the state (§3). **The anchor** is the target under *this* module catalog and at the readiness level of measurement, i.e. the cytotrophoblast; independently reconstructed catalogs reproduce the region and anchor it elsewhere (Note S-O), and output-level scoring does the same (Note S-T), so "anchor" never carries a claim beyond this catalog. **Occupancy** is the share of cells whose top-1 nearest normal neighbour is a member of the boundary named; **depth** is the per-cancer occupancy; **recurrence** is the number of cancers in which a cell is among the five most frequent nearest neighbours. Where a sentence needs the distinction between region and cell and does not make it, the region is meant.
